Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
pediatric
Biotech
DBV peanut allergy patch hits endpoint in phase 3 infant study
DBV chalked up a win for its beleaguered peanut allergy patch candidate, hitting the primary endpoint in a phase 3 clinical trial in infants.
Nick Paul Taylor
Jun 8, 2022 8:40am
100% overall survival data fuel Rocket for flight to regulators
May 20, 2022 10:30am
New AI tools aim to boost objectivity in pediatric trials
May 16, 2022 1:05pm
Gilead unveils pediatric drug development center in Ireland
Apr 6, 2022 1:55pm
FDA puts LogicBio genome editing therapy trial on hold
Feb 2, 2022 8:10am
GSK drops phase 2 viral vector RSV vaccine in infants
Jul 28, 2021 9:26am
